Biopharma Co. Adagio Grabs $309M In Cooley-Led IPO
Adagio Therapeutics Inc., a life sciences company working on antibody-based treatment for COVID-19, began trading Friday after pricing a $309.4 million upsized initial public offering shaped by Cooley LLP and underwriters'...To view the full article, register now.
Already a subscriber? Click here to view full article